Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1530.85
₹7.70(0.59%)
At close: 4:00 PM EST
₹1530.85
₹7.70(0.59%)
Day’s Range― - ―
52-Week Range₹1,237.90 - ₹1,909.55
Previous CloseN/A
Volume91.31K
Average Volume (3M)2.07K
Market Cap
₹190.67B
Enterprise Value₹211.50B
Total Cash (Recent Filing)₹839.20M
Total Debt (Recent Filing)₹23.89B
Price to Earnings (P/E)51.4
Beta0.63
Next Earnings
May 26, 2026EPS Estimate
9.43Next Dividend Ex-DateN/A
Dividend Yield0.47%
Share Statistics
EPS (TTM)8.30
Shares Outstanding138,542,900
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)53.43
Revenue Forecast (FY)₹37.65B
Bulls Say, Bears Say
Bulls Say
Revenue & Cash Flow GrowthSustained revenue and operating cash flow growth reflects durable demand for branded chronic therapies and improved conversion of earnings into cash. This strengthens the company's ability to fund marketing, incremental manufacturing capacity or selective M&A without immediate capital markets dependence.
Strong Margins And Operational EfficiencyRobust gross and operating margins point to pricing power and efficient cost structure from a branded-focused model and mixed in-house/CM manufacturing. Durable margin strength supports reinvestment in salesforce and brands, helping sustain competitive positioning in chronic therapy segments.
Healthy Balance Sheet And Manageable LeverageA solid equity base and moderate leverage provide financial flexibility to absorb regulatory shocks, invest in growth, or pursue bolt-on acquisitions. Lower indebtedness reduces refinancing risk and supports sustained capital allocation to marketing and manufacturing over the medium term.
Bears Say
Free Cash Flow VolatilityWhile FCF has improved, historical volatility in free cash flow increases uncertainty around the company's ability to consistently fund higher marketing spend, capex or acquisitions. Variable FCF complicates multi-quarter planning and raises sensitivity to working capital swings or timing of payments.
Decreasing Cash BalancesA declining cash balance reduces the liquidity buffer available for short-term shocks or opportunistic investments. With modest cash reserves the company may rely more on external financing for large capex or integration of new brands, increasing execution and financing risk over several quarters.
Concentration In Domestic Branded Market & Regulatory RiskHeavy reliance on India branded prescriptions and physician-facing distribution concentrates exposure to local regulatory pricing controls, reimbursement shifts and competitive in-licensing. Structural regulatory or policy changes in India could materially pressure pricing power and volume growth over the medium term.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1237.90 and its highest was ₹1909.55 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹190.67B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is May 26, 2026 which is in 28 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Feb 13, 2026. The company reported ₹8.3 earnings per share for the quarter, missing the consensus estimate of ₹9.625 by -₹1.325.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Annually dividend of ₹7.35 which represents an annual dividend yield of 0.47%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 9.43.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,542,900 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹8.3 in its last earnings report, missing expectations of ₹9.625. Following the earnings report the stock price went down -6.38%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi Consumer Healthcare India Limited
―